Ion channel modulating compounds and uses thereof

• US 7,524,879 B2
• Filed: 06/04/2007
• Issued: 04/28/2009
• Est. Priority Date: 10/06/2000
• Status: Expired due to Term

• Current Assignee: Correvio International SARL (ADVANZ PHARMA Corp. Ltd.)
• Original Assignee: Cardiome Pharma Corp. (ADVANZ PHARMA Corp. Ltd.)
• Inventors: Zolotoy, Alexander R., Plouvier, Bertrand M. C., Sheng, Tao, Wall, Richard A., Zhu, Jeff Jiqun, Yong, Sandro L., Walker, Michael J. A., Beatch, Gregory N.
• Primary Examiner(s): Saeed; Kamal A
• Assistant Examiner(s): BIANCHI, KRISTIN A
• Application Number:
  US11/757,880
• Publication Number:
  US 20080004333A1
• Time in Patent Office: 694 Days
• Field of Search: 514/424
• US Class Current: 514/424
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/4015 having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: C07D 209/36 in position 3, e.g. adrenochrome

Abstract

Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia.

Claims

1. A method of treating postoperative arrhythmia in a warm-blooded animal in need thereof, comprising administering to said animal a therapeutically effective amount of a composition comprising a compound having the following structure:

2. The method of claim 1 wherein administration is by a route selected from the group consisting of oral, topical, parenteral, sublingual, rectal, vaginal, and intranasal.

3. The method of claim 2 wherein the parenteral administration is selected from the group consisting of subcutaneous injection, intravenous injection, intramuscular injection, epidural injection, intrasternal injection, and infusion.

4. The method of claim 2 wherein the oral administration comprises administering an oral dosage form selected from the group consisting of a powder, a granule, a compressed tablet, a pill, a capsule, a cachet, a chewing gum, a wafer, and a lozenge.

5. The method of claim 1 wherein the arrhythmia is selected from atrial arrhythmia and ventricular arrhythmia.

6. The method of claim 5 wherein the atrial arrhythmia is atrial fibrillation.

7. The method of claim 5 wherein the ventricular arrhythmia is ventricular fibrillation.

8. The method of claim 1 wherein the postoperative arrhythmia occurs following cardiac surgery.

9. The method of claim 8 wherein the cardiac surgery is coronary artery bypass surgery.

10. The method of claim 1 wherein the compound is a mixture of enantiomeric or diastereomeric isomers.

11. The method of claim 10 wherein the compound has the following structure:

12. The method of claim 10 wherein the compound has the following structure:

13. The method of claim 1 wherein the compound is an isolated enantiomeric or diastereomeric isomer.

14. The method of claim 13 wherein the compound has the following structure:

15. The method of claim 13 wherein the compound has the following structure:

16. The method of claim 13 wherein the compound has the following structure:

17. The method of claim 13 wherein the compound has the following structure:

18. The method of claim 15 wherein the pharmaceutically acceptable salt is a monohydrochloride salt.